Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 14, 2014; 20(38): 13648-13657
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13648
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13648
Ref. | Biomarker | Sample | Patients | Chemotherapy |
Huang et al[25], 2013 | AMBP | Serum | 17 GC patients | paclitaxel, capecitabine |
Sekikawa et al[26], 2013 | REG Iα | Tissue | 70 GC patients | S-1, Cisplatin |
Okada et al[27], 2013 | FOXM1 | Tissue | 81 GC patients | docetaxel, 5-FU, cisplatin/5-FU, cisplatin |
Sugita et al[28], 2010 | BNIP3 | Tissue | 80 GC patients | 5-FU, irinotecan/docetaxel/cisplatin |
DAPK | ||||
Mitani et al[29], 2007 | REG4 | Serum | 36 GC patients | 5-FU, cisplatin |
- Citation: Aichler M, Luber B, Lordick F, Walch A. Proteomic and metabolic prediction of response to therapy in gastric cancer. World J Gastroenterol 2014; 20(38): 13648-13657
- URL: https://www.wjgnet.com/1007-9327/full/v20/i38/13648.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i38.13648